Navigation Links
AltMed Appoints Drug Discovery Researcher Dr. Christopher Witowski as Director of Laboratory and Processing Services

Sarasota, FL (PRWEB) June 17, 2015

AltMed LLC, the Florida company that brings pharmaceutical industry precision to the development and production of medical cannabis, announced today the appointment of Dr. Christopher Witowski as Director of Laboratory and Processing Services.

Following receipt of his undergraduate degree in Chemistry from Florida State University, Dr. Witowski spent five years conducting research at the University of South Florida while pursuing his Ph.D.

His work included supervising drug discovery screenings of marine macro and microorganisms at the Center for Drug Discovery and Innovation. This was a hands on research initiative that included diving for marine organisms; then extracting, identifying, and analyzing compounds to discover potential cancer therapies, antibiotics, and other anti-infective drugs.

"The Center for Drug Discovery and Innovation is a premier research program that is very relevant to the innovations and breakthroughs that we will be generating in our labs at AltMed," said David Wright, CEO of AltMed. "Dr. Witowski is a rare talent in a new specialty area where those with extensive research experience in natural products drug discovery are difficult to find."

Dr. Witowski will spearhead AltMed's laboratory initiatives leading to research and testing involving cannabidiol (CBD), other cannabinoids, and their dosages and safe usage, while developing formulations that will enable smoke-free treatment of patients.

Dr. Witowski’s research focus has been on making discoveries from the natural environment, hence his fascination with expanding research and knowledge of the cannabis plant.

"I believe in using what nature gives us because nature is a better chemist than any person that will walk this earth can ever be, and we are just beginning to realize the potential of cannabis and the formulation possibilities for treating different ailments," said Dr. Witowski. "Cannabis presents unique possibilities because the crude natural cannabis plant material has therapeutic effects, which will allow us to test and create synergies among various extracts, with the potential to positively impact patients with specific conditions."

Dr. Witowski specializes in the natural products field including plant and microbial extract drug screening, working toward the discovery of new therapeutic treatments. His research has led to a long list of awards and publications.

Dr. Witowski will be based at AltMed's labs at its Sarasota, FL headquarters and he will travel extensively to collaborate with leading cannabis researchers around the world.

About AltMed LLC - AltMed is a fully integrated company that will bring pharmaceutical industry precision to the development, production and dispensing of medical cannabis. Established in early 2014 by a consortium of Sarasota residents, AltMed's Executive Chairman and its CEO are both former senior pharmaceutical executives. Their previous company, MedImmune (acquired by Astra Zeneca in 2007), produces a drug for the prevention of respiratory infections in infants.

Forward-Looking Statements

To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of cultivating, processing, and dispensing high quality medical cannabis to qualified Florida patients; (ii) the legalization of medical grade cannabis production and use by the federal government; (iii) our ability to obtain licensing for medical cannabis production and distribution in Florida; (iv) availability and cost of additional capital; (v) our ability to attract, retain and motivate qualified employees and management; (vi) the impact of federal, state or local government regulations; (vii) competition in the cannabis industry; (viii) our ability to generate revenues and (ix) litigation in connection with our business.

All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. AltMed to Present on Cannabis Investor Webcast
2. Florida Medical Cannabis Leader AltMed Allies With Canada's Vida Cannabis To Build Best-in-Class Expertise
3. Vida Cannabis Allies with Florida Medical Cannabis Leader AltMed to Build Best-in-Class Expertise
4. Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed
5. BrainBank appoints Ludwig Melik as CEO and announces major new investment to fuel growth for its collaborative Innovation Management software
6. HIPAA Secure Now! Appoints Jonathan Krasner to Head Business Development, Grow MSP Partner Base, Help Partners Succeed
7. The Canton Group Appoints Tim Dodge as Chief Marketing Officer
8. Insightlink Communications Appoints New Director of Marketing and Client Engagement
9. Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions
10. PureFormulas Appoints John Tsokos as Director of Emerging Channels
11. Howard University Appoints Dr. Hugh E. Mighty, Dean, College of Medicine & Vice President, Clinical Affairs
Post Your Comments:
(Date:2/19/2020)... ... February 19, 2020 , ... ... a grant of $10,000.00 from the Doug Flutie, Jr. Foundation for Autism. The ... students with autism. , The physical fitness program will include the hiring of ...
(Date:2/19/2020)... ... 19, 2020 , ... The American College of Lifestyle Medicine ... Medicine Residency Curriculum (LMRC). The curriculum is the first comprehensive, applicable and flexible ... by resident involvement, the curriculum has included residents in every aspect of its ...
(Date:2/19/2020)... ... February 19, 2020 , ... MedTech IGNITE Expands Steering ... to Participate in 2020 Cohort , The Massachusetts Medical Device Industry Council ( ... accepting applications from startup founders and CEOs to participate in the 2020 IGNITE ...
(Date:2/19/2020)... (PRWEB) , ... February 19, 2020 , ... ... quality and consistency of healthcare delivery, announced that it will participate in the ... in Orlando, Florida. BPM+ Health will engage healthcare professionals and other stakeholders at ...
(Date:2/19/2020)... , ... February 19, 2020 , ... SEAL SHIELD, LLC ... a result of healthcare-acquired infections (HAIs.) According to The Centers for Disease Control (CDC), ... the large amount of screens that are now acting as an extension of people’s ...
Breaking Medicine News(10 mins):
(Date:2/28/2020)... ... February 27, 2020 , ... At the VA Maryland Health Care System, ... or tablets with the VA Video Connect application. Since its rollout in July 2019, ... secure, live video telehealth appointments. The VA Video Connect app has proven to be ...
(Date:2/26/2020)... ... February 26, 2020 , ... SGF is the largest fertility ... fertility care for over two decades. With seven locations in Northern Virginia, the addition ... 13 reproductive endocrinologists and 1 reproductive urologist. SGF Fairfax’s lab director recently shared just ...
(Date:2/26/2020)... ... February 26, 2020 , ... ... today closing of a $4.5 million financing round led by HOYA Corporation (“HOYA”) ... will be used to complete Anchora's family of single-use laparoscopic suturing devices. , ...
Breaking Medicine Technology: